Silymarin is a standardized extract derived from the seeds of the milk thistle plant (Silybum marianum). It is a complex mixture of flavonolignans, primarily consisting of silybin (silibinin), silychristin, and silydianin, with silybin being the most biologically active and abundant component. In the Indian context, it is widely used as a hepatoprotective agent for various toxic and degenerative liver conditions. Its therapeutic effects are attributed to antioxidant, anti-inflammatory, antifibrotic, and membrane-stabilizing properties. It is classified as a nutraceutical/herbal medicine and is available over-the-counter (OTC) in most formulations.
Adult: 140 mg to 800 mg per day, divided into 2-3 doses. A common standardized dose is 140 mg three times daily. For phosphatidylcholine complex, 100-200 mg twice daily.
Note: Administer with water, preferably with meals to improve tolerance and potentially enhance absorption. Capsules/tablets should be swallowed whole. Do not crush or chew unless specified (e.g., dispersible tablets).
Silymarin exerts hepatoprotective effects through multiple interconnected mechanisms: 1) **Antioxidant Activity**: Scavenges free radicals and reactive oxygen species (ROS). 2) **Membrane Stabilization**: Inhibits the binding of toxins (like amatoxin from death cap mushroom) to hepatocyte membrane receptors and increases membrane stability by reducing lipid peroxidation. 3) **Anti-fibrotic**: Downregulates hepatic stellate cell activation, reducing collagen deposition. 4) **Anti-inflammatory**: Inhibits NF-ÎșB pathway, reducing production of TNF-α and other pro-inflammatory cytokines. 5) **Hepatocyte Regeneration**: Stimulates ribosomal RNA synthesis, promoting protein synthesis and liver cell regeneration. 6) **Iron Chelation**: Silybin can chelate iron, reducing iron-induced oxidative stress.
Pregnancy: Category C (US FDA equivalent). Animal reproduction studies are insufficient. Use during pregnancy only if potential benefit justifies potential risk to the fetus. Not recommended for routine use.
Driving: No known effects on driving ability. However, if rare side effects like dizziness or weakness occur, caution is advised.
| Metformin, Glibenclamide, Insulin | Silymarin may potentiate hypoglycemic effects. Monitor blood glucose levels closely. | Moderate |
| Simeprevir | Silymarin may increase plasma concentration of simeprevir by inhibiting CYP3A4 and OATP1B1/3 transporters. Concomitant use is not recommended. | Major |
| Rosuvastatin, Atorvastatin | May increase statin levels by inhibiting OATP1B1 transporter, potentially increasing risk of myopathy. Monitor for muscle pain. | Moderate |
| Diazepam, Midazolam (CYP3A4 substrates) | May increase sedative effects. Use with caution. | Moderate |
| Cyclosporine | May inhibit P-glycoprotein, potentially increasing cyclosporine bioavailability. Monitor cyclosporine levels. | Moderate |
| Anticoagulants (Warfarin) | Theoretical risk of interaction due to potential CYP2C9 modulation, but clinical evidence is weak. Monitor INR periodically. | Minor |